A boutique medical communications agency that truly delivers

With 24 years of experience in delivering medical communications for the global pharma industry, Eastmond Medicomm is your perfect partner for commercial and medical affairs communications deliverables.



Using a quarter century of direct experience, we have designed a publications process that gets rid of procrastination and delay, and delivers rapid, laser-accurate published material in full compliance with industry standards, including GPP3 and ICMJE.

Live events

Eastmond Medicomm creates enjoyable events that stick in the mind long after they are over. Our creative team consistently delivers event branding that challenges norms. Our events are the only ones anyone remembers.

Digital media

If you can think of it, we can do it. If you haven’t thought of it, then we can deliver on that too — be it videos, animations, apps, games, VR, post-event USBs or the ‘next big thing.’


You can plan carefully, but ultimately you need to adapt. Eastmond Medicomm produces inspiring, pragmatic plans delivered in a manner that understands that everything changes all of the time.

Virtual model

We do not employ staff and we do not run premises. We build project-specific teams from the best, ex-director, medical communications specialists in the world. You can access the best delivery team there is while enjoying outstanding value for money.


Informational videos

Challenge: “Can you make a risk-management video for a loco-regional regulator?” Response: Eastmond Medicomm combined existing client assets with stock graphics and local branding guidelines to produce an 8-minute RMP video. A well-known actor was engaged for the voiceover, and the video was cut such that key information points appeared in time with the script …


Challenge: “Can you get us into NEJM?” Response: Yes and no. The New England Journal of Medicine is the stone-like pinnacle of medical publishing upon which careers have been made and hopes have been dashed. Over 13 years of operation, we have submitted something like eight or so papers to NEJM. Only one of them …